Bristol Myers Earnings Are a ‘Tale of 2 Trends’ as Guidance Falls Short. The Stock Is Falling
Drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price gain of more than 20%, while most of the group has been flat or down. Financial results the company reported early Thursday seem to validate that recent performance,
Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.
Bristol Myers Squibb Co. released sales and profit forecasts for 2025 below Wall Street’s expectations — a sign the company’s ...
Ed: As usual, a disappointing lack of ambition from the senior management to push hard for promotion. They blame the transfer ...
Bristol Palin, the daughter of former Alaska governor Sarah Palin, recently posted a series of videos on Instagram ...
BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion ...
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...
Suzanne Laprise faces a 12-year prison sentence after pleading guilty to attempted first-degree assault in a shooting in the ...
Ontario County Sheriff’s deputies arrested a Fairport man at Bristol Mountain Ski Resort on Wednesday evening following an ...
2don MSN
Two 18-year-old men and a juvenile from New Haven were arrested in Bristol on Tuesday after abandoning a stolen vehicle ...
Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid ...
- Seafood Nutrition Partnership has appointed H-E-B Vice President of Seafood Jason Driskill to serve as the chair of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback